Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ALMR | 8-K | neutral | 2/10 | Alamar Biosciences appointed Robert Ragusa to its Board of Directors, effective September 1, 2026, as a Class I director | Sep 1, 2026 |
| MAZE | 144 | neutral | 3/10 | Jason V. Coloma, an officer of Maze Therapeutics, filed a Form 144 to sell 34,501 shares of common stock, with an estima | Sep 1, 2026 |
| MTEX | 8-K | neutral | 2/10 | Mannatech announced the retirement of Chairman J. Stanley Fredrick effective September 1, 2026, and the appointment of V | Sep 1, 2026 |
| SHPH | 8-K | neutral | 2/10 | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) amended its merger agreement with United Dogecoin Inc., reducing the Miles | Sep 1, 2026 |
| AVXL | DEFA14A | neutral | 6/10 | Anavex Life Sciences filed a DEFA14A on September 1, 2026, confirming that management met with ISS to present its case a | Sep 1, 2026 |
| TARS | 144 | bearish | 5/10 | Former officer Aziz Mottiwala filed a Form 144 notice to sell 77,698 shares (~$5.75M) of Tarsus Pharmaceuticals on Septe | Sep 1, 2026 |
| SAFX | 8-K | neutral | 3/10 | XCF Global filed updated pro forma financials for its proposed acquisition of Southern Energy and DevvStream. The pro fo | Sep 1, 2026 |
| AZN | COURT-RULING | bearish | 3/10 | AstraZeneca's lawsuit challenging Colorado's 340B contract pharmacy protection law (S.B. 71) was dismissed with prejudic | Sep 1, 2026 |
| MEOH | PRESS-RELEASE | bearish | 6/10 | Methanex will indefinitely idle its New Zealand production facilities starting Q1 2027, having sold substantially all of | Sep 1, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics disclosed the repurchase of 127,796 of its own shares between August 24-28, 2026, for a total | Sep 1, 2026 |
| PHGE | 8-K | neutral | 3/10 | BiomX Inc. (PHGE) announced a corporate name change to Tessera Defense and Homeland Security Inc., effective September 1 | Sep 1, 2026 |
| KZIA | 6-K | bullish | 6/10 | Kazia Therapeutics announced preclinical data for paxalisib in two new large-market indications: MSS/pMMR colorectal can | Sep 1, 2026 |
| RARE | PRESS-RELEASE | bullish | 7/10 | Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS (DTX401) gene therapy in glycogen storage disease | Sep 1, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine Total Voting Rights notification under UK Disclosure Guidance and Transparency Rule 5.6.1R, disclosi | Sep 1, 2026 |
| AZN | 6-K | neutral | 1/10 | AstraZeneca filed a routine 6-K notification of admission of 10,072 ordinary shares to trading on the London Stock Excha | Sep 1, 2026 |
| ETST | 8-K | neutral | 4/10 | Earth Science Tech, Inc. (ETST) reported results from its first Annual Meeting of Stockholders held on August 31, 2026. | Sep 1, 2026 |
| RGPX | 8-K | bearish | 6/10 | Regenerex Pharma filed an 8-K disclosing that its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 a | Sep 1, 2026 |
| RAPH | 8-K | neutral | 3/10 | Raphael Pharmaceutical entered into a 12-month, $180,000 managed AI services agreement with AIcreatesAI for digital tran | Sep 1, 2026 |
| AZN | 6-K | neutral | 1/10 | AstraZeneca filed a routine 6-K disclosing its total voting rights as of 31 August 2026. The filing confirms 1,551,043,4 | Sep 1, 2026 |
| CRNX | 25-NSE | bullish | 9/10 | Nasdaq has filed Form 25 to delist Crinetics Pharmaceuticals (CRNX) common stock effective September 1, 2026, following | Sep 1, 2026 |
| LEXX | 8-K | bullish | 6/10 | Lexaria Bioscience Corp. received an AUD$3,666,611.98 (USD$2.6M) R&D tax credit from the Australian Tax Office for its G | Sep 1, 2026 |
| CRNX | 8-K | bullish | 9/10 | Crinetics Pharmaceuticals has been acquired by Vertex Pharmaceuticals in an all-cash merger that closed on September 1, | Sep 1, 2026 |
| BMRN | 8-K | neutral | 3/10 | BioMarin completed its previously announced acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a | Sep 1, 2026 |
| BMRN | PRESS-RELEASE | neutral | 4/10 | BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1, a Phase 1/2a oral small-molecule candidate for h | Sep 1, 2026 |
| GYRE | 8-K | neutral | 4/10 | Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the co | Sep 1, 2026 |
| ZEOX | 8-K | neutral | 2/10 | ZEO filed an 8-K announcing the faculty and guest speaker lineup for its inaugural ZEO Xperience, a three-day regenerati | Sep 1, 2026 |
| ALMS | 8-K | mixed | 6/10 | Alumis reported topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe SLE. The trial did | Sep 1, 2026 |
| BMRA | PRESS-RELEASE | mixed | 6/10 | Biomerica reported fiscal 2026 Q4 net sales of ~$875K (+17% YoY) and a net loss improvement to ~$1.1M, while full-year r | Sep 1, 2026 |
| ACET | 8-K | neutral | 5/10 | Adicet Bio announced completion of the last patient visit for the planned Phase 1 analysis of prula-cel in SLE with or w | Sep 1, 2026 |
| RDHL | 6-K | bullish | 7/10 | RedHill Biopharma announced a transformational acquisition of exclusive global commercialization rights to Ferring's Reb | Sep 1, 2026 |